About Sickle-cell Anemia
Sickle-cell anemia is a disease characterized by the presence of sickle-shaped erythrocytes. While normal erythrocytes have a life span of 120 days, sickle-shaped erythrocytes die within 10 to 20 days. The bone marrow is unable to compensate for the excessive loss of erythrocytes, thereby leading to anemia. It is an inheritable disorder passed on across generations. The prevalence of the sickle-cell gene varies between different ethnic groups and geographical locations.
TechNavio's analysts forecast the Sickle-cell Anemia Therapeutics market in the US to grow at a CAGR of 17.10 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Sickle-cell Anemia Therapeutics market in the US for the period 2015-2019. To calculate the market size, the report considers the revenue generated through the sales of the US FDA-approved drugs used for the treatment of sickle-cell anemia.
TechNavio's report, Sickle-cell Anemia Therapeutics Market in US 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. It covers the Sickle-cell Anemia Therapeutics market landscape in the US and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Vendors
• Bristol-Myers Squibb
Future Prominent Vendors
• Baxter
• Bluebird Bio
• Daiichi Sankyo
• Eli Lilly
• Emmaus Medical
• GlycoMimetics
• HemaQuest Pharmaceuticals
• Mast Therapeutics
• Merck Sharp & Dohme
• Pfizer
• Selexys Pharmaceuticals
Market Driver
• Unmet Medical Needs
• For a full, detailed list, view our report
Market Challenge
• Side Effects Associated with Current Therapies
• For a full, detailed list, view our report
Market Trend
• Increased Focus on Adult Patients
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offering
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Disease Overview
06. Introduction
07. Market Landscape
07.1 Market Overview
07.2 Market Size and Forecast
07.3 Five Forces Analysis
08. Buying Criteria
09. Market Growth Drivers
10. Drivers and their Impact
11. Market Challenges
12. Impact of Drivers and Challenges
13. Market Trends
14. Trends and their Impact
15. Vendor Landscape
15.1 Competitive Scenario
15.1.1 Key News
15.1.2 Mergers and Acquisitions
15.2 Pipeline Analysis
15.3 Market Share Analysis 2014
16. Future Prominent Vendors
17. Key Vendor Analysis
17.1 Bristol-Myers Squibb
17.1.1 Key Facts
17.1.2 Business Overview
17.1.3 Key Product Offerings
17.1.4 Revenue by Geography
17.1.5 Business Strategy
17.1.6 Key Information
17.1.7 SWOT Analysis
18. Other Reports in this Series
List of Exhibits
Exhibit 1: Product Offering for Sickle-cell Anemia Therapeutics Market in US
Exhibit 2: Market Research Methodology
Exhibit 3: Normal erythrocytes and Sickle-shaped Erythrocytes
Exhibit 4: Impact of Sickled Erythrocytes on Blood Flow
Exhibit 5: Structure of Hemoglobin
Exhibit 6: Genetic Basis of Sickle-cell Anemia
Exhibit 7: Global Distribution of Sickle-cell Gene
Exhibit 8: Symptoms of Sickle-cell Disease
Exhibit 9: Inheritance Pattern of Sickle-cell Anemia
Exhibit 10: Blood Sample of Sickle-cell Disease Patients Before and After Stem Cell Transplantation
Exhibit 11: Laboratory Tests Recommended Before Initiation of Hydroxyurea Therapy
Exhibit 12: Facts for Hemoglobin Disorders
Exhibit 13: RuSH Project Sites
Exhibit 14: PHRESH: Primary Focus
Exhibit 15: Sickle-cell Anemia Therapeutics Market in US 2014-2019 (US$ million)
Exhibit 16: Life Expectancy of Sickle-cell Disease Patients in US
Exhibit 17: Sickle-cell Disease Treatment Demonstration Program Regional Collaborative Technical Assistance: Aims of Funding
Exhibit 18: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 19: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
